Progression through the cell cycle is accompanied by activation of the proto-oncogene c-Src, a protein tyrosine kinase. Overexpression of Src leads to tyrosine phosphorylation of multiple protein substrates and cellular transformation. During interphase the Src protein folds back upon itself to stay in the inactive state, with a phophotyrosine residue in one domain at Tyrosine 529 bound by an SH2 domain in the same protein. Activation of c-Src involves protein-tyrosine phosphatase alpha (PTP-alpha, or RPTP-alpha), a transmembrane protein with a cytoplasmic phosphatase domain. A variety of evidence has indicated that PTP-alpha dephosphorylates c-Src at Tyr529, allowing Src to open up and become activated, and that this activation occurs in association with mitosis. To activate Src, PTP-alpha must first open up the folded Src through binding itself to the phosphorylated Src domain, a process blocked by binding of Grb-2 to PTP-alpha at phosphorylated Tyr789. PTP-alpha phosphorylated at Tyr789 also binds to the Src SH2 domain, causing the Src structure to open at Src Tyr529 to become available for dephosphorylation. During mitosis the mitotic kinase Cdc-2 phosphorylates Src, along with other cellular substrates, and in so doing makes Src more prone PTP-alpha dephosphorylation and activation. The activity of PTP-alpha toward Src is also regulated by phosphorylation of PTP-alpha by protein kinase C at serines 180 and 204, releasing the inhibition of PTP-alpha by Grb-2. In the normal cell cycle, Src activity is down-regulated after cell division through dephosphorylation by protein phosphatases and phosphorylation by Csk (C-terminal src kinase) and PTP-alpha dephoshorylation returns the cycle to its interphase condition. The regulation of Src activity during mitosis demonstrates how protein phosphorylation can shifts the delicate equilibrium of molecular interactions and cellular responses.
Contributor:
REFERENCES: Tomas Mustelin and Tony Hunter. Meeting at Mitosis: Cell Cycle-Specific Regulation of c-Src by RPTPa. Sciences stke jan 15, 2002. Xin-Min Zheng and David Shalloway. Two mechanisms activate PTPa during mitosis. The EMBO Journal Vol.20 No.21 pp.6037-49, 2001.
AlphaMOS(巴黎證券交易所-C區-ISIN代碼:FR0000062804-ALM),獲得了CFI.co雜志頒發的“2020年歐洲最佳感官分析解決方案”獎。CFI.co(CapitalFinanc......
磷酸甘油酸突變酶1(PGAM1)通過其代謝活性以及與其他蛋白質(例如α平滑肌肌動蛋白(ACTA2))的相互作用,在癌癥代謝和腫瘤進展中起關鍵作用。變構調節被認為是發現針對PGAM1的高選擇性和有效抑制......
英國制藥巨頭阿斯利康(AstraZeneca)近日宣布,美國食品和藥物管理局(FDA)已授予saracatinib治療特發性肺纖維化(IPF)的孤兒藥資格。孤兒藥是指用于預防、治療、診斷罕見病的藥品,......
2018年12月6日,來自圣迭戈的消息——Illumina公司(納斯達克股票代碼:ILMN)今天宣布推出新型高密度基因分型芯片Infinium?GlobalDiversityArray。這款芯片設計源......
據美國《科學》雜志網站近日報道,位于美國加州的聚變能研究公司TriAlpha最近取得了新的突破,有望在國際熱核聚變實驗反應堆(ITER)采用的大型托卡馬克裝置之外為受控核聚變能利用找到更為經濟的技術路......
法國阿爾法莫斯公司(AlphaMOS)和依托于上海中醫藥大學的上海張江中藥現代制劑技術工程研究中心最近舉行了聯合創辦藥物制劑研發聯合實驗室的揭牌儀式。上海張江中藥現代制劑技術工程研究中心主任阮克鋒主持......
SDS-PAGE異常電泳現象及分析SDS-PAGEHallofShame.pdf 很不錯的東東~~推薦下~......
摘要失巢凋亡是細胞與細胞外基質脫離發生的一種特定的凋亡方式.癌細胞抗失巢凋亡或失巢生存能力可以使之在轉移過程中生存.業已發現癌細胞失巢生存與PI3KPKB/Akt、MAPK這兩條重要信號途徑有關,但是......
近年來在生命科學領域中興起的新技術——Alpha,是一種基于增強的化學發光的均相免疫技術,已廣泛用于各項生物實驗的研究,包括應用于藥物活性測試。Alpha技術包括AlphaScreen和AlphaLI......
近日來自美國堪薩斯州大學醫學院安德森癌癥研究中心的研究人員研究了抗癌藥物曲妥珠單抗(Trastuzumab)在乳腺癌治療中的耐藥機制,證實非受體酪氨酸激酶c-SRC(SRC)是曲妥珠單抗藥物耐藥反應的......